Management Consulting

Integrated Launch Planning

A fully coordinated, holistic approach

Benefit from Alira Health’s full spectrum of strategy and advisory services to ensure successful outcomes for all of your business stakeholders: patients, providers, payers, and suppliers.

Elevating industry best practices and innovation

Integrated launch planning (ILP) is recognized as an essential best practice. Alira Health provides full spectrum support to coordinate key launch deliverables in a transparent, collaborative way. This allows functions and markets across your organization to focus on the path towards launch in a more holistic, integrated way—a critical key to success.

The purpose of the ILP is not to replace functional launch plans—it’s to provide high-level leadership that delivers an integrated view of the whole picture. As your partner, Alira Health will highlight potential needs for analysis and inquiry if delays are anticipated.

Why choose Alira Health?

Whether your in-house teams are launching products across a multitude of therapeutic areas or you’re a BioTech company relying on third-party service providers, we will help you translating your launch strategy into a robust, executable plan.

Our experienced global team will actively engage with your organization to:

  • Structure your launch preparations and define appropriate launch governance
  • Meet with critical workstream teams to identify key deliverables and essential interdependencies
  • Deliver an integrated launch plan tool that is easy to update and provides customized status reports

Connect with a Winning Team

See why Alira Health was named one of the world’s best management consulting firms by Forbes.

Related news

Blog November 17, 2023
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Co-Design Digital Health MedTech Patient Centricity Pharma
Blog November 2, 2023
The Impact of New Treatment Approvals in Oncology on Relative Survival Rates for EU Patients
This article explores the relationship between the number of new cancer treatment approvals and the five-year relative survival of cancer patients across the European Union (EU).
Oncology Pharma
Blog October 16, 2023
How to Co-Design a Solution with Patients to Meet Their Needs
To learn how you can benefit from a co-design approach and how to get started, we spoke with two experts on patient engagement and co-design.
Digital Health MedTech Patient Centricity Patient Engagement Pharma
Blog October 9, 2023
Inflation Reduction Act and Pharma – Navigating Uncertainty
What's the impact of the Inflation Reduction Act on small biotechs, mid-size companies and large pharma players, and how can they prepare?
Biotech Pharma
Publications September 19, 2023
Opportunities and Challenges in the Therapeutic and CDMO Markets
Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth in this CHEManager article.
CDMO Pharma
News August 31, 2023
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
Life Sciences MedTech Pharma Press Release
Publications August 1, 2023
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
EU Pharma Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.